Weight-loss drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound) have already reshaped treatment for obesity and type 2 diabetes. Now, a new study suggests they may be quietly helping with a third condition that often accompanies both: obstructive sleep apnea.
Research published in JAMA Network Open found that obese patients with type 2 diabetes who were taking a GLP-1 receptor agonist were less likely to need CPAP therapy — the machine-and-mask setup that remains the standard treatment for sleep apnea — than patients who weren’t on the drugs. Patients on GLP-1 medications were also less likely to be hospitalized or to die during the study period, the researchers reported.
“These findings align with recent randomized clinical trials showing that [GLP-1 drugs], especially tirzepatide, improved obstructive sleep apnea severity, potentially through weight loss and metabolic or respiratory mechanisms,” wrote the research team, led by Yong Chen, a professor of biostatistics at the University of Pennsylvania’s Perelman School of Medicine.
The likely explanation, according to sleep specialists, comes down to basic anatomy. “When you have a lot of fatty tissue and it’s pretty much everywhere, it narrows vessels and airways. The airway becomes more collapsible,” said Dr. Gary Wohlberg, director of the Sleep Lab at Northwell Health’s South Shore University Hospital, who wasn’t involved in the study. As GLP-1 drugs drive weight loss, that excess tissue around the neck and upper airway shrinks, potentially easing the physical obstruction that causes apnea in the first place.
Wohlberg cautioned that the findings shouldn’t be read as a signal to skip established sleep apnea treatment in favor of a prescription. “We still need to have CPAP as our first line, but this is supportive of what we’re experiencing,” he said, noting that the results track with what clinicians have anecdotally observed as GLP-1 prescriptions have surged. “They’re helping patients in a number of ways with health. Weight loss helps with diabetes. It may help in cardiac disease, and there’s a possibility that there’s a more direct effect on the airway.”
The study adds sleep apnea to a growing list of conditions — including cardiovascular disease and kidney disease — where GLP-1 drugs appear to offer benefits that extend well beyond their original purpose of blood sugar and weight control, even as researchers continue working out exactly how much of the effect is attributable to weight loss alone versus other physiological mechanisms.
